EM2210G "From Reading the Genome for Risk to Rewriting it for Cardiovascular Health" (IM GR 102822)

Purpose and Overview

Atherosclerotic cardiovascular disease (ASCVD) is a heritable, common, complex disease and the leading cause of death in the world. Dr. Kathiresan will review progress in our understanding of the inherited basis for risk as well resistance to ASCVD. He will then turn to approaches to “rewrite” the genome using gene editing to treat ASCVD.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • To understand the two major genetic models for myocardial infarction risk – monogenic and polygenic.
  • To describe how natural resistance mutations lower plasma apoB-containing lipoproteins lifelong in some people and lead to protection against atherosclerotic cardiovascular disease.
  • To understand the development of a new class of medicines, which can edit the genome in an adult and potentially lead to permanent lowering of LDL cholesterol after a single dose.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/28/2022
Course expires: 
11/30/2022
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.Sekar Kathiresan, M.D.
Co-Founder and CEO
Verve Therapeutics

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome